Phase I trial of dimethyl fumarate, temozolomide, and radiation therapy in glioblastoma

BACKGROUND: Dimethyl fumarate (DMF), an oral agent approved for the treatment of relapsing–remitting multiple sclerosis (RRMS), has promising preclinical activity against glioblastoma (GBM). This phase I study sought to determine the recommended phase 2 dose (RP2D) of DMF and evaluate its safety and...

Descripción completa

Detalles Bibliográficos
Autores principales: Shafer, Danielle, Tombes, Mary Beth, Shrader, Ellen, Ryan, Alison, Bandyopadhyay, Dipankar, Dent, Paul, Malkin, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212848/
https://www.ncbi.nlm.nih.gov/pubmed/32642720
http://dx.doi.org/10.1093/noajnl/vdz052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212848/
https://www.ncbi.nlm.nih.gov/pubmed/32642720
http://dx.doi.org/10.1093/noajnl/vdz052

Ejemplares similares